French drug price cuts loom in €10bn savings plan
This article was originally published in Scrip
The French pharmaceutical industry is again under the hammer after the parliament passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period, €3.5bn of which will affect medicines, and probably medical devices, in the form of selected price cuts, together with moves to increase the market share of generics.
You may also be interested in...
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.
Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.